|
|
Optimizing the Multidisciplinary Management of Fibrosing Interstitial Lung Disease: NP Perspectives on Diagnosis, Emerging Therapeutics, and Longitudinal Monitoring
Activity includes Podcast and Interactive Case Studies
|
|
Facebook
LinkedIn
E-Mail
|
Subcategory: Assessment, Diagnosis, Diagnostic Tests, Evidence-Based Guidelines, Exam, Heart/Chest Sounds, Lung Disease, New Medication, Pharmacology, Primary Care, Pulmonary, Radiology, Respiratory, Spirometry, Treatment Plan
(show less)
|
Released: 06/11/2025
Expires: 06/30/2026 (subject to change)
- CE for this activity will not be available after this date.
 | This activity includes transcription. |
Overview
This activity includes a podcast and an interactive case studies module. Learners can choose to complete either or both activities for credit. CE credit will be awarded individually for each activity completed. - Podcast Overview: This educational podcast focuses on the early recognition, diagnosis, and multidisciplinary management of fibrosing interstitial lung diseases (ILD), with a particular emphasis on the nurse practitioner's role in optimizing patient care. Experts Jessica Glennie, NP, and Corinne Young, NP, explore the clinical burden, diagnostic delays, and progressive nature of ILD, underscoring the critical need for timely imaging, pulmonary function testing, and referral. The discussion highlights best practices for monitoring disease progression, emerging antifibrotic therapies, and the importance of holistic support, including pulmonary rehabilitation and palliative care. Nurse practitioners will gain practical insights and tools to enhance outcomes for patients facing this often underdiagnosed and life-altering condition.
- Interactive Case Studies: Step into the clinical journey of a patient with fibrosing interstitial lung disease (ILD) in this interactive case study module. Explore real-world diagnostic challenges, treatment decisions, and strategies for long-term management, including emerging therapies. Strengthen your clinical acumen and elevate patient care in this engaging, evidence-based learning experience.
PROGRAM UPDATE---On October 7, 2025, Nerandomilast received FDA approval as an oral treatment option for idiopathic pulmonary fibrosis (IPF) in adult patients. It is the first and only preferential inhibitor of phosphodiesterase 4B (PDE4B) to be approved in this indication. FDA approves drug to treat idiopathic pulmonary fibrosis | FDA
Objectives
- Describe the epidemiology, pathophysiology, and overarching patient burden of fibrosing interstitial lung diseases (ILDs), including cardinal symptomatology and morbidity/mortality implications.
- Recognize clinical presentation and establish clinical suspicion of fibrosing ILD as a means of achieving timely patient linkage to the guideline-directed diagnostic pathway.
- Examine current guideline recommendations for the diagnosis and longitudinal, multidisciplinary monitoring of patients with fibrosing ILDs, with a focus on idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).
- Review the traditional IPF/PPF treatment paradigm, emphasizing the need for novelty.
- Evaluate the clinical trial evidence, guideline recommendations, and/or regulatory milestones for emerging novel pharmacotherapeutics in the treatment of IPF or PPF.
Speakers
Jessica Glennie, MSN, APRN
Corinne Young, MSN, FNP-C, FCCP
Disclosure
This program was planned in accordance with AANP CE Standards and Policies.
The speakers have the following disclosures:- Jessica Glennie
- BIPI (Speakers Bureau and Advisory Board), United Therapeutics (Advisory Board), and Gossamer Bio (Advisory Board).
- Corinne Young
- Sanofi/Regeneron (Speakers Bureau), Grifols (Speakers Bureau), GSK (Speakers Bureau), and AstraZeneca (Speakers Bureau).
All Planners involved in this activity have no relevant financial relationships to disclose.
All relevant financial relationships have been mitigated.
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Disclaimer
Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
CE Credit Instructions- Read this activity description, including objectives and disclosures.
- Complete the educational content:
- Podcast:
- Click the Play button to be taken to the NP Pulse podcast on Podbean. If you have a different podcast provider that you prefer, launch your preferred podcast app and search for "NP Pulse".
- Listen to all of Episode 152. A participation code will be provided at the end. Make sure to write this code down! You will need this code to unlock access the the post-test and evaluation to complete the activity to earn your CE credit. The code will consist of a LETTERS and NUMBERS. When entering the code in the Participation Code field, make sure you enter the letters and numbers together (no space between them). Letters are not case sensitive.
- Click on the Additional Resources button to review all additional materials provided (handouts, post-test reviews, any other downloadable resources).
- Return to the AANP CE Center. Click on the activity from your CE Activities list and then click the blue Next Steps button:
- A new window will open. Provide and submit the Participation Code, exactly as it was given at the end of the podcast, in the available text field.
- Complete the post-test.
- Submit the activity evaluation to receive full AANP CE/Rx credit and your certificate of completion.
- Interactive Case Studies:
- Complete the Pretest associated with this part of the activity
- Click the Play button to launch the interactive case studies module. This activity will open in a new window. Complete all parts of the interactive case study module and close the window to return to your CE Activities list. We recommend using the "Exit Course" button shown on the final page of the interactive case study module.
- After completing the interactive case studies content, click on the blue Next Steps button.
- Complete the post-test.
- Submit the activity evaluation to receive full AANP CE/Rx credit and your certificate of completion.
Additional Information
For questions or more information concerning this online CE activity, please visit the AANP Help Center to find answers to frequently asked questions and request assistance.
1.95 Contact Hour(s) of CE,
0.65 of which may be applied towards Pharmacology
|
|
|
|
Adding Registration, Please wait...
